SARS-CoV-2–specific B cell detection and therapeutic antibody discovery

About the webinar

To help combat the COVID-19 pandemic, comprehensive characterization of humoral and cellular immune responses to SARS-CoV-2 is essential.

At Miltenyi Biotec, we have developed reliable tools and methods for analyzing and enriching rare populations of SARS-CoV-2-specific B cells. Tune into this webinar to learn how our products and protocols facilitate COVID-19 research and support the discovery and development of therapeutic antibodies against SARS-CoV-2 and other diseases.

Learning objectives:

Understand how antigen specific lymphocytes work together against SARS-CoV-2
Learn about tools and protocols for monitoring and researching on SARS-CoV-2 specific B cells
Get an overview on the generation of monoclonal antibodies from antigen-specific B cells

Presenter

Cristina Conforti Andreoni

2015 till today Global Product Manager and Group Leader Marketing Immunology, Miltenyi Biotec, Germany
2013 – 2015 Global Product Manager Cell Culture, Miltenyi Biotec, Germany
2011 – 2012 Scientific Officer at Ayoxxa (biotech startup from National University of Singapore)
2009 – 2011 Postdoctoral Fellow, A-STAR, SIgN, (Singapore) on dendritic cells and Th17 cells in inflammation
2006 – 2009 PhD Thesis on dendritic cells and danger signals, University of Milan-Bicocca, Italy and A-STAR, SIgN Singapore
2001 – 2006 Bachelor and Master in Medical Biotechnology, University of Milan-Bicocca, Italy